Background: Adoptive T cell therapy (ACT) has proven to be efficient against hematologic malignancies.
As ACT is mostly based on artificial receptors recognizing single antigens expressed
on cancer cells, major limitations include antigen-loss of tumor cells as well as
side effects. Designing T cells with variable antigen targeting limited in time would
have considerable advantages both in terms of safety and efficacy. In order to create
such a flexible but efficient system, we armed T cells with fusion receptors consisting
of the extracellular portion of an antibody-binding-receptor (Fcγ receptor IIIA, synonymous
CD16) and the intracellular domains of CD28 and CD3z. Combining this platform with
different clinically approved monospecific antibodies could provide a versatile treatment
strategy. Variation of the specificity of the antibody and the receptor affinity for
its Fc part could potentially enhance efficacy and safety of either therapy alone.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P07.05
Identification
Copyright
© 2018 Published by Elsevier Inc.
